Christo Shalish

Christo Shalish is Frontier Medicines’ Senior Vice President and Head of Business Development. He joined Frontier with over 30 years of experience in business development, alliance management and scientific research. He was most recently part of the global business unit of Novo Nordisk where he was responsible for global business activities in the cardiometabolic space. Prior to his tenure with Novo Nordisk, Christo led the business development and alliance management functions at Dicerna Pharmaceuticals. While at Dicerna, Christo facilitated collaborations with Roche and Novo Nordisk, leading up to the successful acquisition of Dicerna by Novo Nordisk. He was also responsible for overseeing partnerships with Boehringer Ingelheim, Eli Lilly, Alexion, and Alnylam. Christo brings deep knowledge of the biotech ecosystem from his work at successful companies including Moderna, Warp Drive Bio, Cubist Pharmaceuticals and ActivBiotics. Christo began his career as a research scientist at Massachusetts General Hospital.

Christo received his MBA from Boston University and his Bachelor of Science in Biology from Gettysburg College in Pennsylvania.